BioNTech SE (NASDAQ:BNTX) has a beta value of 0 and has seen 4,265,382 shares traded in the recent trading session. The company, currently valued at $50.13 Billion, closed the recent trade at $207.39 per share which meant it gained $19.11 on the day or 10.15% during that session. The BNTX stock price is -0.98% off its 52-week high price of $209.42 and 82.16% above the 52-week low of $37. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.55 Million shares traded. The 3-month trading volume is 1.89 Million shares.
The consensus among analysts is that BioNTech SE (BNTX) is an Overweight stock at the moment, with a recommendation rating of 2.3. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 6 out of 11 have rated it as a Hold, with 4 advising it as a Buy. 1 have rated the stock as Underweight. The expected earnings per share for the stock is $3.72.
BioNTech SE (NASDAQ:BNTX) trade information
Sporting 10.15% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, May 03 when the BNTX stock price touched $209.45 or saw a rise of 1.51%. Year-to-date, BioNTech SE shares have moved 153.05%, while the 5-day performance has seen it change 18.12%. Over the past 30 days, the shares of BioNTech SE (NASDAQ:BNTX) have changed 81.16%. Short interest in the company has seen 4.75 Million shares shorted with days to cover at 2.51.
BioNTech SE (BNTX) estimates and forecasts
Figures show that BioNTech SE shares have outperformed across the wider relevant industry. The company’s shares have gained +142.82% over the past 6 months, with this year growth rate of 25457.14%, compared to 8.1% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 1382.8% and 1346.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be +1962.1%.
4 analysts offering their estimates for the company have set an average revenue estimate of $1.78 Billion for the current quarter. 4 have an estimated revenue figure of $2.53 Billion for the next quarter concluding in June 01, 2021. Year-ago sales stood $33.02 Million and $49.33 Million respectively for this quarter and the next, and analysts expect sales will grow by 5285.1% for the current quarter and 5027.5% for the next.
Earnings growth for 2021 is a modest +107.1%.
BioNTech SE (NASDAQ:BNTX)’s Major holders
Insiders own 1.18% of the company shares, while shares held by institutions stand at 10.98% with a share float percentage of 11.11%. Investors are also buoyed by the number of investors in a company, with BioNTech SE having a total of 302 institutions that hold shares in the company. The top two institutional holders are Primecap Management Company with over 4.63 Million shares worth more than $377.29 Million. As of December 30, 2020, Primecap Management Company held 1.92% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The other major institutional holder is FMR, LLC, with the holding of over 2.9 Million shares as of December 30, 2020. The firm’s total holdings are worth over $236.3 Million and represent 1.2% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Horizon Fund-Capital Opportunity Portfolio and Primecap Odyssey Aggressive Growth Fund. As of December 30, 2020, the former fund manager holds about 0.91% shares in the company for having 2208696 shares of worth $180.05 Million while later fund manager owns 1.87 Million shares of worth $218.5 Million as of January 30, 2021, which makes it owner of about 0.77% of company’s outstanding stock.